Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Fmr LLC

FMR LLC increased its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,623,881 shares of the company's stock after purchasing an additional 115,898 shares during the period. FMR LLC owned approximately 14.82% of Spyre Therapeutics worth $224,218,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Amalgamated Bank bought a new stake in Spyre Therapeutics in the second quarter valued at $28,000. Quest Partners LLC bought a new position in Spyre Therapeutics in the 2nd quarter worth $36,000. SG Americas Securities LLC bought a new position in Spyre Therapeutics in the 2nd quarter worth $130,000. Intech Investment Management LLC bought a new position in Spyre Therapeutics in the 3rd quarter worth $246,000. Finally, Carlyle Group Inc. bought a new stake in Spyre Therapeutics during the second quarter valued at about $227,000. 80.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on SYRE shares. Wedbush reiterated an "outperform" rating and issued a $45.00 price target on shares of Spyre Therapeutics in a research report on Friday, November 8th. Robert W. Baird lifted their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Finally, Guggenheim boosted their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 25th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Spyre Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $48.57.

Spyre Therapeutics Price Performance

NASDAQ SYRE traded down $0.09 on Tuesday, reaching $27.56. The stock had a trading volume of 280,356 shares, compared to its average volume of 527,196. Spyre Therapeutics, Inc. has a 12-month low of $14.22 and a 12-month high of $47.97. The business's 50-day moving average price is $31.03 and its 200 day moving average price is $29.70.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).